ClinicalTrials.gg
CompletedNCT05684705Updated Jan 14, 2025

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

A Phase 1 interventional study of BV100 in Bacterial Infections, sponsored by BioVersys AG. Completed at 1 site in Austria. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by BioVersys AG · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Read the detailed description

This is a single center, open-label, monocentric, multiple IV dose, phase I study to investigate the penetration of rifabutin into the lung after multiple intravenous administrations of BV100 (rifabutin for infusion) in healthy participants.

02

Conditions studied

  • Bacterial Infections

Browse trials for

03

In context

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

This study's enrollment of 35 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

BioVersys AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who can understand and follow instructions during the study.
  2. Participants have been informed both verbally and in writing about the objectives of the clinical trial, the methods, the potential risks, and the discomfort to which he/she may be exposed and has given written consent to participation in the trial prior to trial start and any trial-related procedure.
  3. Healthy male participants ≥ 18 and ≤ 55 years of age, or female participants ≥ 18 and ≤ 55 years of age of non- defined as follows:

    • Female participants 50 years of age or older, in menopause for 24 consecutive months and not receiving any hormone replacement therapy within 24 months prior to inclusion into the study
    • female participants who underwent surgical sterilization
    • female participants who underwent hysterectomy
    • female participants with documented premature ovarian failure
  4. Healthy participants as defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, 12-lead , vital signs, physical examination, spirometry ( > 75% of predicted), and clinical laboratory tests.
  5. Weight within a range of 19.0 30.0 kg/m2 inclusive.
  6. Healthy male participants with female partners of child-bearing potential must use two methods of , one of which must be a barrier method (e.g., condom) to be used for the duration of the study and for 8 weeks after last IMP dose.
  7. Non-smokers, i.e., one who has abstained from use of tobacco or other nicotine containing products for at least 12 months, confirmed by negative cotinine test.
  8. Having had no febrile or significant infectious illness for at least one month prior to dosing.
  9. The subject is available to complete the study.
  10. The subject is able and willing to comply with the restrictions and requirements of the protocol and, in the opinion of the study physician, can complete the study.

Exclusion criteria

Exclusion Criteria:

  1. As a result of the medical screening process, the study physician considered the subject unfit for the study.
  2. Pregnant or lactating women, or men with female partners, who are not willing to use as defined in inclusion criterion #6.
  3. Known or suspected history of to rifabutin or or to drugs of a similar chemical class including rifampicin, rifapentine, rifaximin; history of allergic reactions leading to hospitalization or any other allergic conditions (including drug allergies, asthma, eczema, anaphylactic reactions but excluding untreated, asymptomatic, seasonal allergies) which the investigator considers may affect the safety of the subject and/or outcome of the study.
  4. History of antibiotic associated severe diarrhea within the last year.
  5. Any medication that inhibits tubular secretion (e.g., Probenecid, H2 receptor antagonists, trimethoprim) within 2 weeks prior to first dosing.
  6. Participants with abnormalities (history, or evidence of second-degree heart block of Mobitz type II, third degree heart block, or any abnormality considered relevant by the investigator), > 450 ms, PR > 210 ms, or QRS duration > 120 ms.
  7. Supine systolic blood pressure > 140 mm Hg or \< 90 mm Hg or diastolic blood pressure > 90 mm Hg or \< 45 mm Hg at Screening or Day 1 prior to dosing (any abnormal blood pressure results may be repeated once and if the repeat result is within the normal range, it is not considered to have met the exclusion criterion). Pulse rate> 90 bpm or \< 45 bpm at Screening.
  8. abnormal values for leukocytes (total WBC), neutrophils, and lymphocytes (total), or values below the lower limit of normal (LLN) at screening. Any abnormal value of these parameters may be repeated and if the repeat result is within the laboratory reference range or not considered relevant by the investigator, it is not considered to have met the exclusion criterion.
  9. (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and creatinine, above the at Screening. Any abnormal value of these parameters may be repeated and if the repeat result is within the laboratory reference range, it is not considered to have met the exclusion criterion.
  10. Any clinical laboratory deviation that is assessed as clinically significant by the investigator (Note the exceptions mentioned in Ex 8 and 9)
  11. History of symptomatic, chronic or recurrent infection (e.g., nausea, vomiting, diarrhea, infection with fever) or any viral (including symptomatic herpes zoster), bacterial (including upper respiratory infection), fungal (non-cutaneous) or parasitic infection within 30 days prior to admission to the clinical unit.
  12. A positive pre-study serology test for surface antigen (HbsAg), virus (HCV) antibodies or (HIV)-1 and/or 2 antibodies.
  13. A positive drug/alcohol screen at screening or day -1.
  14. History of epilepsy, seizures, other neurological disorders, or neuropsychiatric conditions.
  15. Participants who have received any prescribed systemic or topical medication within 2 weeks of the first dose administration or five times the elimination half-life (whichever is longer).
  16. Participants who had used any non-prescribed systemic or topical medication (including herbal remedies) or megadose vitamins (i.e., 20 to 600 times the recommended daily supplement dose) within 7 days prior to dosing, unless in the opinion of the study physician the medication did not interfere with the study procedures or compromise safety.
  17. Participants who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 14 days of the first dose administration.
  18. Regular use of any inducer of metabolism (e.g., barbiturates, rifampin), or medications interfering with Cytochrome P450, Family 3, Subfamily A () are prohibited, comprising inducers, substrates, and inhibitors in the 3 months prior to the first admission to the clinical unit.
  19. Any medication that inhibits active tubular secretion (e.g. Probenecid, H2 receptor antagonists, trimethoprim) within 2 weeks prior to first dosing.
  20. Participants who have participated in a clinical study involving administration of an drug (new chemical entity) within the following time-period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  21. Participants who consume more than 21 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse (one unit of alcohol equals 285 mL of beer [½ pint], one glass [125 mL] of wine, or 30 mL of 40% alcohol by volume distilled spirits).
  22. Excessive consumption of caffeine- or xanthine-containing food or beverages (> 5 cups of coffee a day or equivalent) or inability to stop consuming from 48 hours prior to administration of study treatment.
  23. Any use of drugs-of-abuse or alcohol abuse within 2 years prior to the first admission to the clinical unit.
  24. Inability to understand or communicate reliably with the investigator or considered by the investigator to be unable to or unlikely to co-operate with the requirements of the study.
  25. Any other conditions or factors which in the opinion of the investigator may interfere with study conduct. Failure to satisfy the investigator of fitness to participate for any other reason.
  26. Any significant blood loss: donated one unit (450 mL) of blood or more or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days prior to the first admission to the clinical unit.
  27. Participants who are study site employees or immediate family members of the study site or sponsor employees.
  28. Suspected SARS CoV 2 infection
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    BV100

    7 doses of BV100 (q12h)

    Drug: BV100

Interventions

  • DrugBV100

    Intravenous infusion

    Also known as: Rifabutin for Infusion

06

What researchers measure

Primary outcomes

  1. To assess plasma concentration of rifabutin in healthy participants

    Plasma concentration of rifabutin

    Time frame: 5 Days

  2. To assess epithelial lining fluid concentration of rifabutin in healthy participants

    Concentration of rifabutin in the epithelial lining fluid

    Time frame: 5 days

  3. To assess concentration of rifabutin in alveolar macrophages of healthy participants

    Concentration of rifabutin in the alveolar macrophages

    Time frame: 5 days

Secondary outcomes

  1. Safety and Tolerability of multiple dose administration of BV100 in healthy participants

    Number of Participants with Treatment-Emergent Adverse Events

    Time frame: 13 days

07

Study locations

1 site
  • Medical University of Vienna
    Vienna, A-1090, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Oct 2024, 13 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 13 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2023
First posted
Jan 13, 2023
StartActual
Sep 1, 2023
Primary completionActual
Oct 30, 2024
CompletionActual
Dec 30, 2024
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05684705
Lead sponsor
BioVersys AG
Collaborators
CW-Research and Management GmbH
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Sep 1, 2023
Primary completion
Oct 30, 2024
Completion
Dec 30, 2024
Last update
Jan 14, 2025

Study contacts

Lisa Husband, MD
study director · BioVersys SAS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BV100

Start the discussion